Rapt Therapeutics Sees Significant Drop in Short Interest

Rapt Therapeutics (NASDAQ:RAPT) experienced a notable decrease in short interest during February 2024. As of February 27, short interest fell to 1,340,164 shares, reflecting a substantial drop of 40.2% from the previous total of 2,242,149 shares recorded on February 12. With an average trading volume of 964,859 shares, this results in a short-interest ratio of approximately 1.4 days, indicating that around 5.0% of the company’s shares are currently short sold.

Stock Performance and Market Analysis

On February 27, Rapt maintained a stable trading price of $58.02, contributing to a market capitalization of approximately $1.61 billion. The company’s price-to-earnings (P/E) ratio stands at -5.25, with a beta of 0.49. Over the past 52 weeks, Rapt has seen a low of $5.67 and a high of $58.02. The stock’s 50-day moving average price is $52.37, while the 200-day moving average is $36.15.

Rapt has received mixed reviews from analysts recently. On January 21, Barclays downgraded the stock from an “overweight” rating to an “equal weight” rating, setting a target price of $58.00. Conversely, Wall Street Zen upgraded Rapt to a “hold” rating on March 7. Other analysts have also weighed in, with TD Cowen lowering its rating from “buy” to “hold” on January 20, and Weiss Ratings reaffirming a “sell (d-)” rating shortly thereafter. Currently, one analyst has assigned a Strong Buy rating, one a Buy rating, ten have a Hold rating, and one has rated it as a Sell. According to data from MarketBeat.com, the average rating for Rapt Therapeutics is “Hold,” with a consensus price target of $48.44.

Institutional Investment Trends

In recent months, institutional investors and hedge funds have adjusted their stakes in Rapt Therapeutics. Invesco Ltd. increased its holdings by 18.8% during the fourth quarter, now owning 167,030 shares valued at approximately $5.66 million. Similarly, ADAR1 Capital Management LLC raised its position by 0.4%, bringing its total to 509,679 shares worth about $17.26 million. New investments also came from XTX Topco Ltd. and Voloridge Investment Management LLC, who acquired shares valued at approximately $616,000 and $233,000, respectively. Currently, institutional investors and hedge funds hold a significant portion of the company, accounting for 99.09% of Rapt’s stock.

Rapt Therapeutics, founded in 2013 and headquartered in San Diego, California, is a clinical-stage biotechnology company that focuses on developing innovative therapeutics for autoimmune and allergic diseases. The company’s research platform utilizes tissue-selective immunology to design small molecules and biologic candidates aimed at modulating immune cell trafficking and tissue-resident pathways. Rapt’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), which is currently in clinical trials for atopic dermatitis and allergic asthma.

As investors and analysts continue to monitor Rapt Therapeutics, the company’s strategic developments and market performance will be of significant interest in the coming months.